Skip to main content

Table 1 Summary of the relationship between EGFR copy number, expression, and the patients' clinical-pathological characteristics

From: Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations

clinical-
pathological characteristic
Copy number Expression
  Positive, N/% Negative, N/% P value Positive, N/% Negative, N/% P value
Age(years)       
≤35 5/10.9 4/4.3 0.265c 23/92.0 107/93.9 1.000c
>35 41/89.1 89/95.7   2/8.0 7/6.1  
Lymph node metastasis       
Positive 23/50 49/52.7 0.765a 16/64.0 56/49.1 0.178a
Negative 23/50 44/47.3   9/36.0 58/50.9  
Stage       
0 0/0 2/2.2 0.748a, $ 1/4.0 2/1.8 0.450a, $
I 10/21.7 18/19.4   6/24.0 21/18.4  
II 25/54.3 53/57   11/44.0 67/58.8  
III 10/21.7 20/21.5   7/28.0 22/20.2  
IV 1/2.2 0/0   0/0 1/0.9  
Tumor type       
DCIS 0/0 3/3.2 0.551b, & 1/4.0 2/1.8 1.000c, &
LCIS 0/0 0/0   0/0 0/0  
IDC 44/95.7 83/89.2   23/92.0 104/91.2  
ILC 0/0 3/3.2   0/0 3/2.6  
Other 2/4.3 4/4.3   1/4.0 5/4.4  
ER       
Positive 33/71.7 72/77.4 0.464a 13/52.0 92/80.7 0.002a
Negative 13/28.3 21/22.6   12/48.0 22/19.3  
PR       
Positive 27/58.7 54/58.1 0.943a 5/20.0 76/66.7 0.000a
Negative 19/41.3 39/41.9   20/80.0 38/33.3  
HER2       
Positive 9/19.6 16/17.2 0.733a 5/20.0 29/25.4 0.567a
Negative 37/80.4 77/82.8   20/80.0 85/74.6  
Ki-67 (%)       
< 14 7/15.2 35/37.6 0.007a 17/68.0 67/58.8 0.393a
> 16 39/84.8 58/62.4   8/32.0 47/41.2  
Subtypes       
LUMA 9/19.6 28/30.1 0.628a, ^ 4/16.0 33/28.9 0.010c, ^
LUMB (HER2-NEG) 17/37.0 32/34.4   7/28.0 42/36.8  
LUMB (HER2-POS) 10/21.7 16/17.2   4/16.0 22/19.3  
HER2 2/4.3 6/17.2   1/4.0 7/6.1  
Basal-like 6/13.0 4/4.3   9/36.0 1/0.9  
UC 2/4.3 7/7.5   0/0 9/7.9  
Grade       
I 0/0 0/0 0.921a, # 0/0 0/0 0.001a, #
II 31/67.4 52/55.9   10/40.0 73/64.0  
III 12/26.1 21/22.6   13/52.0 20/17.5  
UC 3/6.5 20/21.5   2/8.0 21/18.4  
  1. aP values (two-sided) calculated using Pearson's chi-square test.
  2. bP values (two-sided) calculated using Fisher's exact test.
  3. cP values (two-sided) calculated using Continuity Correction of Pearson's chi-square test.
  4. $Pearson's chi-square test for stage 0-II and III- IV vs. EGFR status.
  5. &Fisher's exact test for invasive ductal carcinoma and other types vs. EGFR status.
  6. ^Pearson's chi-square test for luminal subtypes and other subtypes vs. EGFR status.
  7. #Grade II and III vs. EGFR status.
  8. DCIS, ductal carcinoma in-situ; LCIS, lobular carcinoma in-situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; Ki-67, Ki-67 proliferation index; LUMA, luminal A; LUMB (HER2-NEG), luminal B (HER2-negative); LUMB (HER2-POS), luminal B (HER2-positive); UC, unclassified.